Sequential administration of PD‑1 inhibitor and cetuximab causes pneumonia.
PD-1 inhibitor
cetuximab
drug-induced lung injury
head and neck cancer
nivolumab
pembrolizumab
pneumonitis
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
11
01
2023
accepted:
26
04
2023
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Severe drug-induced lung injury (DLI) has been reported to be associated with sequential administration of osimertinib, a third-generation tyrosine kinase inhibitor, following a programmed cell death ligand 1 (PD-L1) inhibitor. However, the relationship of sequential treatment with an anti-epidermal growth factor receptor (EGFR) antibody and PD-1 inhibitor with the risk of DLI remains to be elucidated. The present study conducted a retrospective review of the medical records of a total of 179 patients with head and neck cancer who had received treatment with cetuximab and/or a PD-1 inhibitor (nivolumab or pembrolizumab) at Chiba University Hospital (Chiba, Japan) between September 2014 and December 2020. The incidence of pneumonia and the clinical background characteristics of the patients were analyzed. The patients were classified into subgroups for analysis of the outcomes in this study: Patients who had received sequential, but not concurrent, cetuximab and PD-1 inhibitor treatment (Group C+P; n=43); patients who had received cetuximab-containing chemotherapy, but not a PD-1 inhibitor (Group C; n=101); and patients who had received PD-1 inhibitor-containing chemotherapy, but not cetuximab (Group P; n=35). The rates of DLI in the three groups were: Group C+P, 18.6%; Group C, 7.9%; and Group P, 11.4%. Prior use of ICI was not associated with any increase in the risk of DLI. DLI is seen frequently in patients receiving sequential PD-1 inhibitor and anti-EGFR antibody therapy.
Identifiants
pubmed: 37274471
doi: 10.3892/ol.2023.13874
pii: OL-26-1-13874
pmc: PMC10236250
doi:
Types de publication
Journal Article
Langues
eng
Pagination
288Informations de copyright
Copyright: © Arai et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Clin Med. 2018 Oct 15;7(10):
pubmed: 30326612
Am J Surg Pathol. 2000 Jan;24(1):19-33
pubmed: 10632484
Thorax. 2003 Oct;58(10):872-5
pubmed: 14514942
Ann Oncol. 2020 Apr;31(4):507-516
pubmed: 32139298
Oral Oncol. 2021 Feb;113:105129
pubmed: 33360023
Respiration. 2004 Jul-Aug;71(4):301-26
pubmed: 15316202
Thorax. 2008 Sep;63 Suppl 5:v1-58
pubmed: 18757459
Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28
pubmed: 11770832
Dysphagia. 2010 Jun;25(2):139-52
pubmed: 19711127
Radiographics. 2000 Sep-Oct;20(5):1245-59
pubmed: 10992015
Cancer Manag Res. 2017 Jun 14;9:207-213
pubmed: 28652812
Cancer Chemother Pharmacol. 1998;42(6):497-503
pubmed: 9788577
Lancet Oncol. 2017 Aug;18(8):1104-1115
pubmed: 28651929
Chest. 2017 Aug;152(2):271-281
pubmed: 28499515
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
ESMO Open. 2022 Apr;7(2):100404
pubmed: 35219244
Ann Oncol. 2011 May;22(5):1078-1087
pubmed: 21048039
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33414264
Eur Respir J. 2022 Oct 27;60(4):
pubmed: 35332071
JAMA Oncol. 2016 Dec 01;2(12):1607-1616
pubmed: 27540850
Acta Otorhinolaryngol Belg. 1994;48(2):165-70
pubmed: 8209679
Cancer Sci. 2021 Apr;112(4):1495-1505
pubmed: 33098725
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Histopathology. 2014 Oct;65(4):549-60
pubmed: 24621097
Respir Investig. 2013 Dec;51(4):260-77
pubmed: 24238235
Head Neck. 2022 Jul;44(7):1528-1544
pubmed: 35393753
Am J Respir Crit Care Med. 2015 Dec 1;192(11):1373-86
pubmed: 26623686
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544